SCHEMBL12632007

SCHEMBL12632007

C[C@H](CN(C)C)[C@H](O)C1CCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.45
SLC6A4 P31645 3/20 0.45
SLC6A3 Q01959 3/20 0.45
TP53 P04637 1/20 0.35
KDM4E B2RXH2 2/20 0.34
GMNN O75496 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
BLM P54132 1/20 0.34
PMP22 Q01453 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SHBG P04278 1/20 0.33
CA12 O43570 2/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
MMP2 P08253 2/20 0.32
CA9 Q16790 2/20 0.32
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12631952 0.98 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3TP53KDM4E
SCHEMBL12631967 0.98 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3TP53KDM4E
SCHEMBL12632005 0.79 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3TP53KDM4E
SCHEMBL12631966 0.78 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3TP53KDM4E
SCHEMBL12631948 0.78 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3TP53KDM4E
SCHEMBL24715426 0.76 TP53 (0.52) SLC6A2SLC6A4SLC6A3TP53KDM4E
SCHEMBL11797019 0.76 TP53 (0.41) SLC6A2SLC6A4SLC6A3TP53KDM4E
SCHEMBL1205147 0.76 TP53 (0.52) SLC6A2SLC6A4SLC6A3TP53KDM4E
SCHEMBL27747569 0.76 TP53 (0.52) SLC6A2SLC6A4SLC6A3TP53KDM4E
SCHEMBL13909502 0.76 SHBG (0.50) SLC6A2SLC6A4SLC6A3TP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455521-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-06-04 US disclosed
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors DNPEP, PEPD, ACE SLC6A2 3389/4885SLC6A4 3809/4885SLC6A3 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.